{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:41:22Z","timestamp":1761046882143,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM121322"],"award-info":[{"award-number":["P20GM121322"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54GM104942"],"award-info":[{"award-number":["U54GM104942"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Filgrastim is a human granulocyte colony\u2010stimulating factor (G\u2010CSF). There are limited data on dosing filgrastim in obesity. The objective of this study was to compare filgrastim pharmacokinetic parameters for morbidly obese and non\u2010obese patients after a single subcutaneous dose of filgrastim dosed per actual body weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective, matched\u2010pair study (NCT01719432) included patients \u226518\u00a0years of age, receiving filgrastim at 5\u00a0\u03bcg\/kg with a weight &gt;190% of their ideal body weight (IBW) for \u201cmorbidly obese\u201d patients or within 80%\u2013124% of IBW for matched\u2010control patients. The control group was prospectively matched for age (within 10\u00a0years), degree of neutropenia, and gender. Filgrastim doses were not rounded to vial size, to allow more accurate assessment of exposure. Blood samples were collected at 0 (prior to dose), 2, 4, 6, 8, 12, and 24\u00a0h after the first subcutaneous administration of filgrastim.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 30 patients were enrolled in this prospective pharmacokinetic study, with 15 patients assigned to each arm. Non\u2010compartmental analysis showed that the systemic clearance (Cl) was 0.111 \u00b1 0.041\u00a0ml\/min in the morbidly obese group versus 0.124 \u00b1 0.045\u00a0ml\/min in the non\u2010obese group (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.44). Additionally, the mean area under the curve (AUC<jats:sub>0\u201024h<\/jats:sub>) was 49.3 \u00b1 13.9\u00a0ng\/ml \u00d7 min in the morbidly obese group versus 46.3 \u00b1 16.8\u00a0ng\/mL x min in the non\u2010obese group (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.6). No differences were seen in maximum concentrations (C<jats:sub>max<\/jats:sub>) between the two groups (morbidly obese: 48.1 \u00b1 14.7\u00a0ng\/ml vs. non\u2010obese: 49.2 \u00b1 20.7\u00a0ng\/ml (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.87)). The morbidly obese group had a numerically higher, but not statistically significant, increase in time to maximum concentration (T<jats:sub>max<\/jats:sub>) compared to the non\u2010obese group (544 \u00b1 145\u00a0min vs 436 \u00b1 156\u00a0min (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.06), respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Calculating subcutaneous filgrastim doses using actual body weight appears to produce similar systemic exposure in morbidly obese and non\u2010obese patients with severe neutropenia.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2646","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T13:09:42Z","timestamp":1636722582000},"page":"53-57","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non\u2010obese controls"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-773X","authenticated-orcid":false,"given":"Aaron W.","family":"Stewart","sequence":"first","affiliation":[{"name":"Department of Pharmacy West Virginia University Hospital Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Shillingburg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy West Virginia University Hospital Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Petros","sequence":"additional","affiliation":[{"name":"School of Pharmacy West Virginia University Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics West Virginia University Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Piktel","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute Robert C. Byrd Health Sciences Center West Virginia University Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Moses","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute Robert C. Byrd Health Sciences Center West Virginia University Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura F.","family":"Gibson","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute Robert C. Byrd Health Sciences Center West Virginia University Morgantown West Virginia USA"},{"name":"Department of Microbiology, Immunology and Cell Biology West Virginia University School of Medicine Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute Robert C. Byrd Health Sciences Center West Virginia University Morgantown West Virginia USA"},{"name":"Osborn Hematopoietic Malignancy and Transplantation Program West Virginia University Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Cumpston","sequence":"additional","affiliation":[{"name":"Department of Pharmacy West Virginia University Hospital Morgantown West Virginia USA"},{"name":"Osborn Hematopoietic Malignancy and Transplantation Program West Virginia University Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448050-00007"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3854-x"},{"volume-title":"Prevalence of Obesity and Severe Obesity among Adults: United States, 2017\u20132018. NCHS Data Brief, no 360","year":"2020","author":"Hales CM","key":"e_1_2_8_4_1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318100-000000000-00000"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.8.1081"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02010-15"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9436"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.019"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175323"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417667"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.10068"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19381"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.445"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp574"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199120020-00002"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427010-00003"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.2849.2849"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010376966"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011534529622"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2646","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:12Z","timestamp":1761045792000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/phar.2646"],"URL":"https:\/\/doi.org\/10.1002\/phar.2646","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"2021-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}